C4 Therapeutics Inc (NAS:CCCC)
$ 4.06 -0.24 (-5.58%) Market Cap: 286.59 Mil Enterprise Value: 114.99 Mil PE Ratio: 0 PB Ratio: 1.25 GF Score: 60/100

C4 Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) Transcript

Apr 26, 2023 / 03:00PM GMT
Release Date Price: $3.05
Brad Canino
Stifel Financial Corp. - Analyst

Great. Thanks, everyone, for continuing to join us on our second day of the inaugural Stifel Targeted Oncology Days. My name is Brad Canino, senior analyst here at Stifel. I'm happy to continue the fireside chat session with C4 Therapeutics. And I've got with me Andrew Hirsch, President and CEO; and Stew Fischer, Chief Scientific Officer. So, thank you both for joining me and sitting down for a conversation.

Andrew Hirsch
C4 Therapeutics, Inc. - President, CEO & Director

Great. Thanks, Brad, for having us.

Stew Fischer
C4 Therapeutics, Inc. - Chief Scientific Officer

Thanks, Brad.

Questions & Answers

Brad Canino
Stifel Financial Corp. - Analyst

So we're going to jump right into trying to cover all of the assets, which might be an impossible feat. But we're going to do our best. On the lead asset, CFT7455 or IKZF1 and IKZF3 degrader -- just open with current comments and what you can share about the status of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot